Click on the “Search Now” button to search for research studies enrolling people like you. Need help getting started? Click on “Tips for Searching Studies” to find resources and assistance to help you find studies.

Search Results: Treatment + Breast Cancer + Triple Negative + Stage 1 (2 results)

1 through 2 of 2
Treating Early-Stage BRCA, or PALB2-Associated Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab)

Early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation

Treating Early-Stage HER2-Negative, BRCA, or PALB2-Associated Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab)

This study will look at how well the drugs Niraparib (a PARP inhibitor) and Dostarlimab (an immunotherapy) treat early-stage breast cancer in people with an inherited BRCA1, BRCA2 or PALB2 mutation.  

More info
Screening for Cancer DNA in the Blood after Treatment for Early-Stage TNBC and/or a BRCA Mutation; Followed by Study Comparing Niraparib with Placebo for People with Cancer DNA found in their Blood (ZEST)

Early-stage TNBC or early-stage breast cancer with a BRCA mutation

Using ctDNA Blood Test to Screen for Cancer DNA after Treatment for Early-Stage TNBC and/or an Inherited or Tumor BRCA Mutation; Followed by Study Comparing Niraparib with Placebo for People with Cancer DNA found in their Blood (ZEST)

This study will enroll people with early-stage triple negative breast cancer or people with an inherited or acquired BRCA1 or BRCA2 mutation who have completed treatment (or are still in treatment with hormone therapy) for screening using a blood test known as circulating tumor DNA (ctDNA). Individuals who test positive for ctDNA may be eligible to participate in a randomized study to receive the PARP inhibitor, niraparib or a placebo and undergo close monitoring with imaging (CT scans). The study will look at the safety and efficacy of niraparib plus monitoring compared with placebo plus monitoring for people who test positive for cancer cells in their blood but who have no evidence of cancer recurrence.

More info
Additional Results on Treatment + Breast Cancer + Triple Negative + Stage 1
22 results
Clinical Trial Official Title
NCT02689427 Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
NCT04427293 Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
NCT02977468 Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
NCT03979508 Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
NCT03546686 Peri-Operative Ipilimumab+Nivolumab and Cryoablation in Women With Triple-negative Breast Cancer
NCT02938442 Vaccination of Triple Negative Breast Cancer Patients
NCT05333874 CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage
NCT04333706 A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
NCT04331067 Cabiralizumab in Combination With Nivolumab and Neoadjuvant Chemotherapy in Patients With Localized Triple-negative Breast Cancer
NCT04959474 SABR-CaRe in Early Stage Breast Cancer
NCT02945579 Eliminating Surgery or Radiotherapy After Systemic Therapy in Treating Patients With HER2 Positive or Triple Negative Breast Cancer
NCT02593175 Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
NCT03562637 Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
NCT04139993 RBX7455 Before Surgery for the Treatment of Operable Breast Cancer
NCT02276443 Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
NCT03012100 Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
NCT05144698 RAPA-201 Therapy of Solid Tumors
NCT03424005 A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer
NCT04584255 Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
NCT02488967 Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT03596073 Topical Calcipotriene Treatment for Breast Cancer Immunoprevention
NCT01042379 I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Research Search Tool Sponsored By:

Merck & Co., Inc.

This resource was made possible through an independent grant from Merck & Co., Inc.